Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of TAGraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Previous Exposure to HypOmethylatiNG Agents

NCT05442216 is registered in ClinicalTrials.gov with Joshua Zeidner as lead sponsor.

NCT NCT05442216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05442216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of TAGraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Previous Exposure to HypOmethylatiNG Agents
Lead sponsor
Joshua Zeidner
Phase
Phase 2
Overall status
Recruiting
Start date
May 1, 2024
Completion date
July 21, 2031
Enrollment
53 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia